C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
about
Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional studyHuman epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular diseaseLink between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatmentPeriodontitis and diabetes: a two-way relationshipOverview of the metabolic syndrome; an emerging pandemic of public health significance.Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysisAge Related Shift in Visceral Fat.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?Effects of low- and high-glycemic index/glycemic load diets on coronary heart disease risk factors in overweight/obese men.Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.The relationship between the severity of coronary artery disease and epicardial adipose tissue depends on the left ventricular function.Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals.Consequences of Weight Cycling: An Increase in Disease Risk?The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studyK-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.Self-Reported Periodontitis and Incident Type 2 Diabetes among Male Workers from a 5-Year Follow-Up to MY Health Up Study.Calculating insulin resistance in the primary care setting: why should we worry about insulin levels in euglycemic patients?Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus.Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approachesInfluence of fibrinogen and C-RP on progression of peripheral arterial disease in type 2 diabetes: a preliminary report.Oral antidiabetic agents as cardiovascular drugs.Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.Treating the metabolic syndrome.Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus.Insulin sensitivity in African-American and white women: association with inflammation.Cognitive function, dementia and type 2 diabetes mellitus in the elderly.Interplay between proteins and metabolic syndrome-A review.Circulating Prolidase Activity in Patients with Myocardial Infarction.Insulin resistance and overweight-obese women with polycystic ovary syndrome.Remediable hyperglycaemia in a patient with polymyalgia rheumatica.Chronic inflammation - inflammaging - in the ageing cochlea: A novel target for future presbycusis therapy.2007 ESH‐ESC Guidelines for the management of arterial hypertension
P2860
Q24633407-5F896D5A-48E8-4F66-AA32-85EEC7C4C531Q25257027-4DA22C5D-ADB5-4AC4-AE75-3E785C81E933Q26860246-68B0EFD5-1FD6-441A-B49F-5F62499B124CQ27023000-D223C5CA-402F-4AAB-8659-069091B4BF26Q30366107-528CEB7F-3339-4EC8-B76D-40415EB9C4CFQ33526734-E7FD63C1-B548-4DE4-95CF-B9DE3702BB12Q33601355-775823E1-50E2-403E-80A1-E775E53FEDDBQ33776230-DF133CF6-5FE3-4DE8-B110-7A7D9E58A8EBQ34023548-9F5D23E5-1F28-47AB-8AD4-CCC51D182B52Q34113864-71737E24-2EC8-481A-BF9E-DCE315AE4E79Q34449870-F183C7FF-B5A0-40A6-9098-103A2FB5382CQ34469694-95067090-A73A-4DB6-A29C-E524305395AFQ34524071-A6A01B0D-69F5-4E89-AC1A-6FB0CC268C2AQ34562668-18A77901-F81F-42A3-8599-59A9792A69A3Q35076036-32BB79CD-0256-404C-B4B2-E00447417AE1Q35876408-257BC5F0-D52F-42BE-936B-9C2F302140B2Q35999499-1FA09030-4B60-4C4A-8B2E-DE6CEF7BFC40Q36207896-F8A1DB67-0033-41AE-984B-D41AD0173A1DQ36502062-983FA7B5-BD16-46E7-AD03-1A5E15A01478Q36608474-361CD3C8-7B5D-4A98-8ADF-A1D7CCB4ACD2Q36686775-FB1FBD2C-F4E2-4369-AEEB-0D824D5BFDD8Q36697741-F5462326-3420-4AB1-B3B0-487972FEEC45Q36760107-6B05CA64-9DC2-4B9A-8F02-56D6087D5FD2Q36772880-F9406E04-E4C1-46FD-91ED-0462A6C6DCDFQ36815978-3FCF5DB4-5C88-485C-893C-23A5369AF316Q36892489-4A475856-6F46-495D-AEE4-63EFAB1F4186Q37357299-D952B616-DC9F-442A-AD2F-A532140BD4BBQ37832122-67B27360-3445-4E25-856E-5B17415B42E5Q38517201-407B73F3-675E-4313-890E-6E0B513720F0Q38616533-410E1468-8D03-48F2-B8CE-38E32DF15B4DQ43244951-DAF549CD-CB2B-4324-A908-F85D1A095A13Q46879922-45E71D5F-5B76-482E-98EF-AD6C03E09DCDQ47582552-A985E543-466D-45D1-A665-862B8CE6A554Q56970799-16CEB380-8594-4EE6-BB0A-132110EABF75
P2860
C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
C-reactive protein, its role i ...... tment with thiazolidinediones.
@en
C-reactive protein, its role i ...... tment with thiazolidinediones.
@nl
type
label
C-reactive protein, its role i ...... tment with thiazolidinediones.
@en
C-reactive protein, its role i ...... tment with thiazolidinediones.
@nl
prefLabel
C-reactive protein, its role i ...... tment with thiazolidinediones.
@en
C-reactive protein, its role i ...... tment with thiazolidinediones.
@nl
P2860
P921
P1433
P1476
C-reactive protein, its role i ...... tment with thiazolidinediones.
@en
P2093
P2860
P304
P356
10.1111/J.1464-5491.2004.01296.X
P577
2004-08-01T00:00:00Z